# A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)

> **NCT06836037** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 56 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Efinopegdutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06836037
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-05
- **Primary completion:** 2023-02-02
- **Final completion:** 2023-02-02
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2025-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06836037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06836037, "A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06836037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*